A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Pheon Therapeutics
Kivu Bioscience Inc.
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
National Cancer Institute (NCI)
AbbVie
Eli Lilly and Company
Nammi Therapeutics Inc
Revolution Medicines, Inc.
Pfizer
Alterome Therapeutics, Inc.
Institut Paoli-Calmettes
RasCal Therapeutics, Inc.
Tomsk National Research Medical Center of the Russian Academy of Sciences
ViroMissile, Inc.
Erasca, Inc.
National Institutes of Health Clinical Center (CC)
Poseida Therapeutics, Inc.
MacroGenics
Revolution Medicines, Inc.
City of Hope Medical Center
SN BioScience
Eli Lilly and Company
PAQ Therapeutics, Inc.
Degron Therapeutics Co.
Bristol-Myers Squibb
Abramson Cancer Center at Penn Medicine
University of Southern California
Actym Therapeutics, Inc.
Chongqing Precision Biotech Co., Ltd
HUYABIO International, LLC.
HUYABIO International, LLC.
Ikena Oncology
City of Hope Medical Center
Memgen, Inc.
Revolution Medicines, Inc.
GONGCHU Biotechnology Co., Ltd
Day One Biopharmaceuticals, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Trishula Therapeutics, Inc.
Novita Pharmaceuticals, Inc.
Trishula Therapeutics, Inc.
NextPoint Therapeutics, Inc.
Nuvation Bio Inc.
Celldex Therapeutics